FOR IMMEDIATE RELEASE

Cardiology P.C. at Princeton Baptist Medical Center Treats First Case in Alabama in a Medical Device Clinical Study for Resistant Hypertension

BIRMINGHAM, Ala. – August 26, 2015 Baptist Health System and Cardiology, P.C. Research in Birmingham, Ala., is one of seven centers in the United States conducting a study to evaluate a novel device – MobiusHD™ – to help lower high blood pressure. Farrell Mendelsohn, M.D. at Cardiology P.C., was the first in Alabama to treat a patient with resistant hypertension with the MobiusHD™ device on June 18th, 2015, at Princeton Baptist Medical Center.

The CALM-FIM_US study is evaluating the investigational MobiusHD™ device, a catheter-delivered implant permanently placed in the carotid artery of the neck. It is designed to treat patients with a condition known as resistant hypertension, which occurs when a person’s blood pressure remains high (systolic reading of 160 mmHg or greater) despite taking at least three different medications to lower it. CALM is an abbreviation for “Controlling and Lowering Blood Pressure with the MobiusHD™ - A Prospective Multicenter Safety Study.”

“Hypertension is an epidemic in America, and resistant hypertension is the worst kind,” said Dr. Mendelsohn. “Resistant hypertension significantly increases the risk of stroke and heart attack and anything that can have an effect on this disease will translate into a huge clinical benefit for millions of Americans.”

The MobiusHD™ device is placed in the carotid artery sinus using a catheter similar to those used in a cardiovascular procedure. The catheter is inserted through a small puncture in the groin and advanced to the carotid artery sinus under fluoroscopic (x-ray) guidance. Once the MobiusHD™ device is in place, it is designed to increase the signal generated by the arterial baroreceptors. Baroreceptors are blood pressure sensors in the carotid sinus and are part of the body’s natural system to regulate blood pressure.

“Participating in this trial is extremely exciting,” said Dr. Mendelsohn. “Our physicians at Cardiology, P.C. Research are world leaders in carotid artery stenting. The techniques we have learned translate into expert deployment of the MobiusHD™ device in the carotid artery.”

The CALM-FIM_US study is sponsored by Vascular Dynamics, Inc. and is a prospective, open-label, multicenter, first-in-man trial. For more information about the trial at The Baptist Health System and
Cardiology P.C. Research, please call (205) 780-4330. Caution: Investigational device – limited by United States law to investigational use.

About the Baptist Health System
Baptist Health System, a not-for-profit 501(c) corporation and one of the largest health systems in Alabama, owns four hospital campuses, including Princeton (in Birmingham), Shelby (in Alabaster), Walker (in Jasper) and Citizens (in Talladega) as well as the largest network of employed primary- and specialty-care physicians providing coordinated care across central Alabama. The system includes graduate medical education programs and active clinical research in multiple specialties. Baptist Health System is committed to providing compassionate, high-quality, innovative health care and empowering its communities to achieve their best health. Baptist Health System is a ministry of the churches of the Birmingham Baptist Association, whose representatives elect the Board of Trustees. It was founded in 1922 by a group of local Baptist congregations. For more information please visit [BaptistHealthAlabama.org](http://BaptistHealthAlabama.org).

About Vascular Dynamics, Inc
Vascular Dynamics, Inc (VDI), based in Mountain View, California, was one of the nine companies chosen in 2012 by the FDA to participate in the Early Feasibility Study Investigational Device Exemption (IDE) Pilot Program. VDI is conducting clinical trials in the US and Europe to evaluate the safety and performance of the MobiusHD™ device. The studies are open-label, controlled, multi-center, first-in-human clinical trials. The studies are being conducted in up to ten centers in the US and currently eight centers in Europe. The CALM-FIM_US study represents one of the first FDA approvals of an IDE following the FDA’s issuance of draft guidance on IDEs for early feasibility studies. The intent of the FDA’s guidance is to foster early-stage development of medical devices within the US to address clinical needs and improve patient care, particularly when alternative treatments or assessments are unavailable.

###